Overall rank by patents
#31,376
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 11 technology areas, active 2023–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G06V (IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING).
The verdict
Dermalog holds 8 US patents across 11 technology areas, rank #31,376 of 50,000 tracked assignees.
Dermalog Jenetric Gmbh has been granted 8 US utility patents between 2023 and 2024, placing Dermalog Jenetric Gmbh at rank #31,376 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.8 claims per patent with primary concentration in G06V (IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING). As a Foreign Corporation, Dermalog Jenetric Gmbh is one of the more focused assignees in the PatentsView dataset. By volume, Dermalog sits between Delonaco Limited (8 patents, rank #31,372) and Diamir, Llc (8 patents, rank #31,380) - the closest US assignees by grant volume. The composite Innovation Score of 45.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2024, with 8 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Dermalog Jenetric Gmbh's 9.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Dermalog Jenetric Gmbh against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
DELONACO LIMITED
8 patents
DELUXE MEDIA INC.
8 patents
DEMARAY, LLC
8 patents
DENSO KOREA AUTOMOTIVE CORPORATION
8 patents
DFB SORIA, LLC
8 patents
DIABLO RACING INC.
8 patents
DIABLO TECHNOLOGIES INC.
8 patents
DIAMIR, LLC
8 patents
DERMALOG JENETRIC GMBH
8 patents
What this shows Dermalog holds 8 patents at rank #31,376, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #31,376 in granted patent volume.
Other assignees with the most granted patents in Dermalog's primary technology class.
Dermalog's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 24% higher than 76% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 4 | 50.0% |
| 2024 | 4 | 50.0% |
Top 11 of 11 technology areas
Overall rank by patents
#31,376
Across all tracked assignees
45.2 out of 100
How to use this portfolio
Dermalog's 8 grants land it in the top 24% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.